Literature DB >> 8335044

Sparse data analysis.

L Aarons1.   

Abstract

In recent years there has been a growing interest in techniques capable of analyzing sparse data, particularly gathered during Phase III clinical trials, and there is now pressure on manufacturers to obtain more kinetic and dynamic information from Phase III studies. Techniques for the analysis of sparse data are reviewed drawing on a number of examples taken from pharmacokinetic and pharmacodynamic experiments.

Mesh:

Year:  1993        PMID: 8335044     DOI: 10.1007/BF03220012

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  19 in total

1.  Smooth nonparametric maximum likelihood estimation for population pharmacokinetics, with application to quinidine.

Authors:  M Davidian; A R Gallant
Journal:  J Pharmacokinet Biopharm       Date:  1992-10

2.  Nonparametric maximum likelihood estimation for population pharmacokinetics, with application to cyclosporine.

Authors:  A Mallet; F Mentré; J L Steimer; F Lokiec
Journal:  J Pharmacokinet Biopharm       Date:  1988-06

3.  The population pharmacokinetics of theophylline in neonates and young infants.

Authors:  E S Moore; R G Faix; R C Banagale; T H Grasela
Journal:  J Pharmacokinet Biopharm       Date:  1989-02

4.  Premarketing observational studies of population pharmacokinetics of new drugs.

Authors:  L B Sheiner; L Z Benet
Journal:  Clin Pharmacol Ther       Date:  1985-11       Impact factor: 6.875

5.  Estimation of population pharmacokinetic parameters using destructively obtained experimental data: a simulation study of the one-compartment open model.

Authors:  F T Lindstrom; D S Birkes
Journal:  Drug Metab Rev       Date:  1984       Impact factor: 4.518

Review 6.  Estimating population kinetics.

Authors:  S L Beal; L B Sheiner
Journal:  Crit Rev Biomed Eng       Date:  1982

7.  Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharm Sci       Date:  1982-12       Impact factor: 3.534

Review 8.  Population pharmacokinetics. Theory and clinical application.

Authors:  B Whiting; A W Kelman; J Grevel
Journal:  Clin Pharmacokinet       Date:  1986 Sep-Oct       Impact factor: 6.447

9.  A population analysis of the pharmacokinetics and pharmacodynamics of midazolam in the rat.

Authors:  L Aarons; J W Mandema; M Danhof
Journal:  J Pharmacokinet Biopharm       Date:  1991-10

10.  Evaluation of theophylline pharmacokinetics in a pediatric population using mixed effects models.

Authors:  M S Driscoll; T M Ludden; D T Casto; L C Littlefield
Journal:  J Pharmacokinet Biopharm       Date:  1989-04
View more
  9 in total

Review 1.  Pharmacokinetics of nonsteroidal anti-inflammatory drugs in synovial fluid.

Authors:  R O Day; A J McLachlan; G G Graham; K M Williams
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

2.  Comparison of some practical sampling strategies for population pharmacokinetic studies.

Authors:  E N Jonsson; J R Wade; M O Karlsson
Journal:  J Pharmacokinet Biopharm       Date:  1996-04

3.  Discrimination between rival dosing histories.

Authors:  E N Jonsson; J R Wade; G Almqvist; M O Karlsson
Journal:  Pharm Res       Date:  1997-08       Impact factor: 4.200

Review 4.  Pharmacokinetic and pharmacodynamic data and models in clinical trials.

Authors:  J L Steimer; M E Ebelin; J Van Bree
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Jan-Mar       Impact factor: 2.441

5.  Population pharmacokinetics of ifosfamide and its dechloroethylated and hydroxylated metabolites in children with malignant disease: a sparse sampling approach.

Authors:  T Kerbusch; J de Kraker; R A Mathĵt; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

6.  Pharmacokinetics of ciprofloxacin in the human eye: a clinical study and population pharmacokinetic analysis.

Authors:  N Morlet; G G Graham; B Gatus; A J McLachlan; C Salonikas; D Naidoo; I Goldberg; C M Lam
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

7.  Pharmacological properties of a new antimalarial bisthiazolium salt, T3, and a corresponding prodrug, TE3.

Authors:  Olivier Nicolas; Delphine Margout; Nicolas Taudon; Sharon Wein; Michèle Calas; Henri J Vial; Françoise M M Bressolle
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

Review 8.  Pharmacokinetic and pharmacodynamic issues in the treatment of parasitic infections.

Authors:  G Edwards; S Krishna
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-17       Impact factor: 3.267

9.  Population Pharmacokinetics of Valproic Acid in Pediatric and Adult Caucasian Patients.

Authors:  Paulo Teixeira-da-Silva; Jonás Samuel Pérez-Blanco; Dolores Santos-Buelga; María José Otero; María José García
Journal:  Pharmaceutics       Date:  2022-04-07       Impact factor: 6.525

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.